Biotech Movers

Updated October 14, 2026

Stocks with the most signal activity right now: fund position changes, insider purchases, and upcoming catalysts from 20 specialist biotech hedge funds. Ranked by composite activity score.

How the activity score works

What counts as a mover?

Any biotech stock with recent signal activity: new or changed fund positions from the latest 13F filings, insider purchases in the last 30 days, or an upcoming catalyst within 90 days. Stocks are ranked by an activity score that weights these signals.

How often is this updated?

This page refreshes every hour. Fund position data updates quarterly after 13F filing deadlines. Insider signals are ingested daily from SEC EDGAR Form 4 filings. Catalyst dates are refreshed weekly.

What does the activity score mean?

The activity score combines the number of funds with recent position changes, insider buying activity and dollar volume, catalyst proximity, and fund convergence. Higher scores indicate more concurrent signal activity around a stock.

Are exits and trims included?

Yes. Fund exits and trims appear in the table because they are actionable signals. A multi-fund exit from a stock is just as informative as a multi-fund accumulation.

596 active tickers25 with insider buys40 catalysts in 30d

Ticker	Fund Signal	Funds↕	Insider Buys↕	Next Catalyst↕	Score?↓
SYRE Spyre Therapeutics, Inc.	Held Driehaus Capital, Avoro Capital Advisors +13	9	—	17d Ph2	260
TNGX Tango Therapeutics Inc.	Exited Avoro Capital Advisors, EcoR1 Capital +13	9	—	168d Ph2	245
CYTK Cytokinetics Incorporated	Exited Driehaus Capital, Avoro Capital Advisors +12	8	—	351d Ph3	230
XENE Xenon Pharmaceuticals Inc.	Trimmed Driehaus Capital, OrbiMed Advisors +7	8	2 $1.7M	109d Ph3	225
DYN Dyne Therapeutics Inc.	Exited Avoro Capital Advisors, EcoR1 Capital +10	5	1 $40K	656d Ph3	225
RNA Avidity Biosciences Inc.	Exited Driehaus Capital, Avoro Capital Advisors +12	—	—	198d Ph2	215
RLAY Relay Therapeutics Inc.	Exited Driehaus Capital, EcoR1 Capital +11	6	—	564d Ph3	215
CGON CG Oncology, Inc.	Exited Driehaus Capital, Avoro Capital Advisors +11	4	—	168d Ph2	215
CELC Celcuity Inc.	Added Driehaus Capital, Avoro Capital Advisors +10	8	—	474d Ph2	210
CMPS COMPASS Pathways plc	Added Driehaus Capital, EcoR1 Capital +10	6	—	778d Ph3	210
CLDX Celldex Therapeutics Inc.	New Driehaus Capital, EcoR1 Capital +8	7	—	17d Ph3	205
AXSM Axsome Therapeutics Inc.	Added Driehaus Capital, RA Capital Management +9	6	—	48d Ph2	200
KOD Kodiak Sciences Inc.	Added Driehaus Capital, EcoR1 Capital +3	4	82 $157.0M	137d Ph3	200
GPCR Structure Therapeutics Inc.	Trimmed Driehaus Capital, EcoR1 Capital +10	11	—	168d Ph2	200
CNTA Centessa Pharmaceuticals plc	Exited Driehaus Capital, Avoro Capital Advisors +11	—	—	78d Ph2	200
INSM Insmed Incorporated	Exited Driehaus Capital, Baker Bros. Advisors +10	7	—	78d Ph3	200
SRPT Sarepta Therapeutics Inc.	Exited Avoro Capital Advisors, EcoR1 Capital +10	1	—	17d Ph3	200
AKRO Akero Therapeutics Inc.	Exited Avoro Capital Advisors, EcoR1 Capital +11	—	—	1233d Ph3	200
CRNX Crinetics Pharmaceuticals Inc.	Added Driehaus Capital, EcoR1 Capital +8	5	—	17d Ph2	195
RVMD Revolution Medicines Inc.	Added Driehaus Capital, Avoro Capital Advisors +9	10	—	229d Ph2	195
APGE Apogee Therapeutics Inc.	Trimmed Driehaus Capital, Avoro Capital Advisors +9	3	—	47d Ph2	190
APLS Apellis Pharmaceuticals Inc.	Exited Driehaus Capital, Avoro Capital Advisors +10	—	—	254d Ph2	185
PCVX Vaxcyte Inc.	Exited Driehaus Capital, Avoro Capital Advisors +9	5	—	109d Ph3	185
IMVT Immunovant Inc.	Held Baker Bros. Advisors, OrbiMed Advisors +8	4	—	17d Ph2	185
COGT Cogent Biosciences Inc.	Exited Baker Bros. Advisors, RA Capital Management +9	9	—	168d Ph2	185
EWTX Edgewise Therapeutics, Inc.	Added Driehaus Capital, EcoR1 Capital +8	6	—	109d Ph2	180
DSGN Design Therapeutics, Inc.	Added Driehaus Capital, Avoro Capital Advisors +7	2	—	4d Ph3	175
QURE uniQure N.V.	Added Avoro Capital Advisors, EcoR1 Capital +8	5	—	—	175
ALKS Alkermes plc	Added Driehaus Capital, Avoro Capital Advisors +7	7	—	47d Ph2	170
KYMR Kymera Therapeutics Inc.	Trimmed Driehaus Capital, EcoR1 Capital +8	8	—	259d Ph2	170
MDGL Madrigal Pharmaceuticals Inc.	Trimmed Driehaus Capital, Avoro Capital Advisors +8	6	—	78d Ph3	170
IDYA IDEAYA Biosciences Inc.	Exited Driehaus Capital, Baker Bros. Advisors +8	6	—	93d Ph3	170
ORKA Oruka Therapeutics, Inc.	Exited Driehaus Capital, Avoro Capital Advisors +8	7	—	259d Ph2	170
PRTA Prothena Corporation plc	Exited EcoR1 Capital, Perceptive Advisors +3	—	6 $5.8M	—	170
AAVXF Abivax S.A.	Exited Baker Bros. Advisors, RA Capital Management +8	6	—	78d Ph2	170
MBX MBX Biosciences, Inc.	Added Driehaus Capital, EcoR1 Capital +7	7	—	474d Ph3	165
NGNE Neurogene Inc.	Added Driehaus Capital, Avoro Capital Advisors +7	7	—	778d Ph2	165
ROIV Roivant Sciences Ltd.	Exited Avoro Capital Advisors, Baker Bros. Advisors +8	4	—	—	165
MRSN Mersana Therapeutics Inc.	Exited Avoro Capital Advisors, EcoR1 Capital +9	—	—	—	165
SLDB Solid Biosciences Inc.	Exited EcoR1 Capital, RA Capital Management +6	6	—	1d Ph2	165
NAMSW NewAmsterdam Pharma Co N.V.	Exited EcoR1 Capital, Baker Bros. Advisors +5	4	1 $227K	47d Ph3	165
AMLX Amylyx Pharmaceuticals, Inc.	Added Driehaus Capital, Avoro Capital Advisors +7	7	—	—	160
DFTX Definium Therapeutics, Inc.	Added Driehaus Capital, Avoro Capital Advisors +7	10	—	—	160
ARGX argenx SE	Exited Driehaus Capital, EcoR1 Capital +7	5	—	47d Ph2	160
AVTX Avalo Therapeutics, Inc.	Added Avoro Capital Advisors, Baker Bros. Advisors +7	8	—	—	160
INBX Inhibrx Biosciences, Inc.	Exited RA Capital Management, Perceptive Advisors +2	2	6 $2.0M	259d Ph2	160
ASND Ascendis Pharma A/S	Trimmed Driehaus Capital, Avoro Capital Advisors +7	7	—	259d Ph3	155
RYTM Rhythm Pharmaceuticals Inc.	Trimmed Driehaus Capital, OrbiMed Advisors +6	8	—	17d Ph2	155
TARS Tarsus Pharmaceuticals Inc.	Trimmed Driehaus Capital, OrbiMed Advisors +7	7	—	78d Ph2	155
VKTX Viking Therapeutics Inc.	Trimmed Driehaus Capital, Avoro Capital Advisors +7	3	—	260d Ph3	155

Showing 50 of 596

Get movers before the market opens

Fund moves, insider buys, and catalyst alerts — delivered free every Monday.

See why SYRE is active — and what comes next

AI context on every fund move, insider trade, and catalyst. Full access for 14 days. No card required — no charge for 14 days. Cancel anytime.

Start 14-Day Free Trial

Drill into any signal

Fund Convergence

See which stocks multiple specialist funds are buying at once

Catalyst Calendar

Every PDUFA date, Phase 3 readout, and AdCom in one view

Insider Trading

When executives buy their own stock — the strongest bullish signal

Cash Runway

Which biotechs are running low on cash and face dilution risk

Short Squeeze

High short interest + fund buying + upcoming catalyst = squeeze setup

Signal Rankings

Every signal in one composite score — ranked by conviction

13F Changes

What top biotech funds bought and sold in the latest 13F filing

Smart Money Moves

New positions and exits from 20 specialist biotech funds this quarter

Want AI context on every signal? Start free trial →